Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First baseline data of the Klinefelter ItaliaN Group (KING) cohort: clinical features of adult with Klinefelter syndrome in Italy.
Pasquali D, Chiodini P, Simeon V, Ferlin A, Vignozzi L, Corona G, Lanfranco F, Rochira V, Calogero AE, Bonomi M, Pivonello R, Balercia G, Pizzocaro A, Giagulli VA, Salacone P, Aversa A, Accardo G, Maggi M, Lenzi A, Isidori A, Foresta C, Jannini EA, Garolla A; KING, Klinefelter ItaliaN Group. Pasquali D, et al. Among authors: pivonello r. J Endocrinol Invest. 2022 Sep;45(9):1769-1776. doi: 10.1007/s40618-022-01816-4. Epub 2022 May 24. J Endocrinol Invest. 2022. PMID: 35608733 Free PMC article.
Failure of long-term therapy with sodium valproate in Cushing's disease.
Colao A, Pivonello R, Tripodi FS, Orio F Jr, Ferone D, Cerbone G, Di Somma C, Merola B, Lombardi G. Colao A, et al. Among authors: pivonello r. J Endocrinol Invest. 1997 Jul-Aug;20(7):387-92. doi: 10.1007/BF03347989. J Endocrinol Invest. 1997. PMID: 9309536
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.
Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G. Grottoli S, et al. Among authors: pivonello r. J Endocrinol Invest. 2005 Dec;28(11):978-83. doi: 10.1007/BF03345335. J Endocrinol Invest. 2005. PMID: 16483175
Pegvisomant in acromegaly: why, when, how.
Colao A, Arnaldi G, Beck-Peccoz P, Cannavò S, Cozzi R, degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R, Ghigo E. Colao A, et al. Among authors: pivonello r. J Endocrinol Invest. 2007 Sep;30(8):693-9. doi: 10.1007/BF03347452. J Endocrinol Invest. 2007. PMID: 17923803 Review. No abstract available.
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.
De Martino MC, Auriemma RS, Brevetti G, Vitale G, Schiano V, Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R. De Martino MC, et al. Among authors: pivonello r. J Endocrinol Invest. 2010 Oct;33(9):663-70. doi: 10.1007/BF03346667. Epub 2010 Jul 1. J Endocrinol Invest. 2010. PMID: 20595800 Clinical Trial.
427 results